Blue cone monochromatism (BCM) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Blue cone monochromatism (BCM) is a rare X-linked congenital cone dysfunction syndrome, caused by mutations in the OPN1LW/OPN1MW gene cluster on the X chromosome. The cluster contains a single OPN1LW and one or more copies of the OPN1MW gene and controls the expression of the red (L, long wavelength) and green (M, middle wavelength) cone photoreceptor opsins. The genes expressing the opsin for the third cone subtype, S (short-wavelength) or blue cones (OPN1SW), and the rod pigment are autosomal and not affected in BCM. Consequently, vision in affected males is subserved only by S cone and rod function, as no functional L or M cones are present in the retina while Tritan discrimination, which has been reported to deteriorate with increasing illuminance and scotopic perception are retained.

The prevalence of Blue cone monochromatism (BCM) varies between 1 to 1.75 cases per 100,000 population. Colour discrimination is severely impaired from birth and BCM patients typically present reduced visual acuity (6/24 to 6/60), pendular nystagmus, photophobia, and often have a myopic pattern.

The competitive landscape of Blue cone monochromatism (BCM) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Blue cone monochromatism (BCM) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Blue cone monochromatism (BCM) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Blue cone monochromatism (BCM) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

 

S. No    Asset               Company                                 Stage

1          ADVM-062        Adverum Biotechnologies, Inc.   -

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033